ProShare Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

ProShare Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,741	Closed	-$224K	–	2372
2021 Q3	$224K	Sell	12,741 -12,636	-50%	-$148K	﹤0.01%	1735
2021 Q2	$246K	Buy	+25,377	New	+$239K	﹤0.01%	2019

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

ProShare Advisors's TRIL Position: Q4 2021 in Review

ProShare Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 12,741 shares — an estimated $224K sold.

ProShare Advisors first reported a position in TRIL in Q2 2021 and held it in 2 quarters. The position peaked at $246K in Q2 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

ProShare Advisors reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
ProShare Advisors sold 12,741 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $224K.
ProShare Advisors first reported a position in Trillium Therapeutics Inc. in Q2 2021 and held it in 2 quarters.
ProShare Advisors's Trillium Therapeutics Inc. position peaked at $246K in Q2 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on ProShare Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.